BioCentury | Feb 1, 2020
Company News

Any chance left for safer opioids?

...language on the labels dissuades payers from reimbursing them. For example, the label for Embeda morphine/naltrexone...
...reported in these studies has not yet been established. There is no evidence that the naltrexone...
BioCentury | Dec 12, 2019
Company News

Dec. 11 Company Quick Takes: Kite, Alkermes, argenx, Reblozyl, Denovo-Sunesis

...said it will submit an MAA to EMA early next year. FDA warns Alkermes over Vivitrol...
...warning letter last week to Alkermes plc (NASDAQ:ALKS)related to an ad for opioid antagonist Vivitrol naltrexone...
...receptor type 2B; TOP2 - Topoisomerase II Elizabeth S. Eaton, Staff Writer luspatercept (ACE-536) Vivitrol, naltrexone (Medisorb naltrexone, Vivitrex, XR-NTX) Yescarta...
BioCentury | Nov 19, 2019
Company News

Alkermes expands CNS pipeline with Rodin acquisition

...to its neuropsychiatry portfolio, which includes schizophrenia drug Aristada aripiprazole lauroxil and addiction treatment Vivitrol naltrexone...
BioCentury | Oct 23, 2019
Company News

With MS approval looming, Alkermes restructures to seek sustainable profits

...and increases the number of immunostimulatory tumor-killing immune cells. Alkermes' primary growth drivers are Vivitrol naltrexone...
BioCentury | Aug 30, 2019
Clinical News

Aug. 30 Clinical Quick Takes: Pharnext falls on FDA request for second Phase III study, plus Genentech, Novartis and Seqirus

...The company had been planning to submit an NDA for the oral solution of baclofen, naltrexone...
BioCentury | Jul 30, 2019
Company News

July 29 Company Quick Takes: Dupixent sales boost Sanofi; plus Twist, J&J, Alkermes and more

...Vivitrol Amneal Pharmaceuticals Inc. (NYSE:AMRX) terminated its inter partes review petition challenging a patent for Vivitrol...
...Amneal Pharmaceuticals Inc. (NYSE:AMRX) terminated its inter partes review petition challenging a patent for Vivitrol naltrexone...
...protein, efmoroctocog alfa (BIIB031, rfviiifc, Long-lasting rFACTOR VIII) Ingrezza, valbenazine (MT-5199, NBI-98854, VMAT2) Vivitrol, naltrexone (Medisorb naltrexone, Vivitrex, XR-NTX) Alkermes Amneal...
BioCentury | Jun 3, 2019
Product Development

There are opportunities to eradicate opioid misuse: Investors and innovators should seize them

...utilizes FDA-approved formulations of methadone, a full μ opioid agonist; buprenorphine, a partial agonist; or naltrexone...
...ER) formulations will facilitate compliance and OUD management, including for patients living in rural areas Naltrexone...
...thus inhibiting their effects, including reward and analgesia Patients need to be detoxified before initiating naltrexone...
BioCentury | Apr 25, 2019
Company News

Alkermes sinks after reporting Aristada sales miss

...Weight Gain Test" ). For the quarter, sales of alcohol and opioid dependence drug Vivitrol naltrexone...
...FactSet. Chris Lieu, Staff Writer Aristada, aripiprazole lauroxil (ALKS 9070, ALKS 9072) samidorphan/olanzapine (ALKS 3831) Vivitrol, naltrexone (Medisorb naltrexone, Vivitrex, XR-NTX) Alkermes...
BioCentury | Apr 12, 2019
Product Development

Changing models and minds to improve access to addiction treatment

...to individuals who are going through withdrawal or tapering off opioid use. Alkermes’ Vivitrol extended-release naltrexone...
...opioid receptor antagonist that blocks the effects of exogenous opioids, preventing relapse by preventing euphoria. Vivitrol...
...live in a state that has not yet expanded Medicaid. Medicaid covers methadone, buprenorphine and Vivitrol...
BioCentury | Apr 10, 2019
Company News

U.S. fraud charges pummel Indivior shares

...found that newer extended-release formulations of MATs for opioid use disorder, including Sublocade and Vivitrol naltrexone...
...Romeo, Staff Writer Sublocade (Brand), RBP-6000 (Compound #), buprenorphine (Generic) Suboxone sublingual film, buprenorphine/naloxone Vivitrol, naltrexone (Medisorb naltrexone, Vivitrex, XR-NTX) Alkermes...
Items per page:
1 - 10 of 624